DAT-2645 for BRCA-Mutated or HRD-Positive Ovarian Cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new drug called DAT-2645 for ovarian cancer patients with specific genetic changes (BRCA mutations or HRD-positive status) who haven't responded well to standard treatments. The drug may help slow or stop cancer growth in patients whose tumors have DNA-repair problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed epithelial ovarian cancer (the most common type of ovarian cancer)
- BRCA1/2 genetic mutation OR HRD-positive status (DNA-repair deficiency in cancer cells)
- Cancer that didn't respond to standard treatment or caused too many side effects
- Received no more than 5 previous cancer treatments
- At least one measurable tumor on imaging
- Good overall health (able to perform light activities; ECOG score 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called DAT-2645 for people with advanced solid tumors that have a specific DNA repair problem (like a BRCA gene change). It aims to see if the drug is safe and effective when standard treatments have stopped working.
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
This trial tests a new oral drug, DAT-1604, for people with advanced solid tumors who have run out of standard options. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors.
This Phase 1 trial tests two experimental drugs (CKD-215 and D215) in adults with advanced ovarian, fallopian tube, or peritoneal cancer that has a BRCA gene mutation. The goal is to find safe and effective doses of these drugs for treating this type of cancer.
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
Hear when a new Advanced or Metastatic Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.